IMELDA_2B | R Documentation |
Kaplan-Meier digitized data from IMELDA, figure 2B (PMID 25273343). A reported sample size of 284 for a primary endpoint of PFS in breast cancer.
IMELDA_2B
A data frame of 185 observations and 3 variables:
time | event time (in months) | |
event | OS event indicator (0 : no event, 1 : event) |
|
arm | treatment arms (bevacizumab, bevacizumab_capecitabine) | |
Gligorov J, Doval D, Bines J, et al. Maintenance capecitabine and bevacizumab versus bevacizumab alone after initial first-line bevacizumab and docetaxel for patients with HER2-negative metastatic breast cancer (IMELDA): a randomised, open-label, phase 3 trial. Lancet Oncol 2014; 15: 1351–60.
summary(IMELDA_2B)
kmplot(IMELDA_2B)
Add the following code to your website.
For more information on customizing the embed code, read Embedding Snippets.